中欧和东欧:临床癌症创新的炉?
Mark Lawler1, Susan Bhatti2, Pawel Przewiezlikowski3
1Johnston Cancer Research Centre, Queen's University Belfast, BT9 7AE, UK; Cancer Drug Development Forum, Clos Chapelle-aux-Champs 30, Brussels 1200, Belgium.
Journal of cancer policy
|October 17, 2025
概括
欧盟27-CEE地区的临床研究面临挑战,但为癌症药物开发提供了重大机会. 呼吁采取行动提出了改善临床试验和患者获得新疗法的解决方案.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 欧盟公共卫生 欧盟公共卫生
背景情况:
- 在整个欧洲,癌症护理和新型治疗的获取不均,特别是在欧盟27个地区的西部和东部之间.
- 俄罗斯入侵乌克兰已经扰乱了该地区的癌症治疗,研究和临床试验.
- 中欧和东欧联盟 (EU27-CEE) 各国在临床研究中面临多重因素的挑战,包括患者获取,试验进行,教育,基础设施和监管障碍.
研究的目的:
- 确定欧盟27-CEE临床研究领域的挑战和机遇.
- 提出一个行动呼吁,以加强欧盟27-CEE国家的癌症临床试验.
- 改善患者获得先进的癌症疗法和药物开发的机会.
主要方法:
- 在制定"行动呼吁"时,采用了咨询方法.
- 分析欧盟27-CEE国家当前的临床试验环境.
- 确定该地区临床研究的障碍和促进因素.
主要成果:
- 欧盟27-CEE拥有活跃的临床试验环境,拥有熟练的劳动力,高质量的数据和不断增长的制药行业.
- 波兰是生物医学创新的典范,也是一个富有成效的临床试验生态系统.
- 欧盟27-CEE地区的患者对全球癌症药物开发产生重大影响.
结论:
- 多利益相关者合作和以患者为中心的策略对于简化试验启动和进行至关重要.
- 实施"行动呼吁"可以增强欧盟27-CEE的癌症临床试验环境.
- 加强患者获得尖端癌症治疗的权力,需要解决区域差异和后勤挑战.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Preclinical Development: Overview
5.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


